PLEASANTON, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- ZELTIQ®, (Nasdaq:ZLTQ) a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it has priced an underwritten public offering of 4,500,000 shares of its common stock, all of which are being offered by selling stockholders, at a price to the public of $13.00 per share. The selling stockholders have also granted the underwriters a 30-day option to purchase up to 675,000 additional shares. Goldman Sachs & Co. and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, and Canaccord Genuity Inc. and William Blair & Company, L.L.C. are acting as co-managers for the offering.
A registration statement relating to the offering has been filed with the Securities and Exchange Commission (the "SEC"). A preliminary prospectus supplement relating to the offering has been, and a final prospectus supplement relating to the offering will be, filed with the SEC. Copies of the preliminary prospectus supplement and, when available, the final prospectus supplement, relating to these securities may be obtained by visiting the SEC's website at www.sec.gov or from Goldman Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by calling toll-free at (866)-471-2526, or from J.P. Morgan Securities LLC at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by calling 866-803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
Cautionary Information Regarding Forward Looking Statements
The statements in this press release regarding ZELTIQ's intentions with respect to the public offering are forward-looking statements that are subject to significant risks and uncertainties, and actual results could differ materially from those projected. These risks and uncertainties include, without limitation, risks and uncertainties related to satisfaction of customary closing conditions related to the public offering. There can be no assurance that the public offering will be completed on the anticipated terms, or at all. The forward-looking statements in this release speak only as of this date, and ZELTIQ disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.